DexCom (NASDAQ:DXCM) Given New $147.00 Price Target at Raymond James

DexCom (NASDAQ:DXCM – Get Free Report) had its price target lifted by stock analysts at Raymond James from $131.00 to $147.00 in a report released on Wednesday, Benzinga reports. The firm currently has a “strong-buy” rating on the medical device company’s stock. Raymond James’ target price suggests a potential upside of 22.45% from the company’s […]

Related Keywords

United States ,Stifel Nicolaus ,Raymond James ,Leerink Partnrs ,Stevenr Altman ,Steven Robert Pacelli ,Raymond Jame ,Harbour Investments Inc ,Dexcom Inc ,Valley National Advisers Inc ,Thompson Siegel Walmsley ,Atlas Capital Advisors ,Wells Fargo Company ,Dexcom Company Profile ,Securities Inc ,Get Free Report ,Com Stock Down ,Director Steven ,Director Steven Robert Pacelli ,Capital Advisors ,Valley National Advisers ,National Advisers ,Dexcom Share ,Dexcom Real Time ,Dexcom Daily ,Dexcom ,Nasdaq Dxcm ,Dxcm ,Medical ,25213110 ,Boost Price Target ,